Special sessions announced for LEAPS Design Lab
The LEAPS Virtual Design Lab will be held online June 9–10 by invitation only. If you are interested in attending the panel session, please contact easmall@mit.edu. New Session: Real World Platform...
View ArticleFoCUS Monthly Recap: may 2020
NEW RESOURCES Paying for Cures Toolkit updated with new material for patients and developers Version 2 of the free online resource adds new sections for patients and developers, and provides new...
View ArticleLEAPS Monthly Recap: may 2020
LEAPS JUNE VIRTUAL DESIGN LABTwo exciting new confirmed developments New Session: Real World Platform Strategies Through the Lens of a Pandemic The ongoing pandemic has generated a flurry of...
View ArticleAdaptive Reimbursement: Innovating for Patient Access and Better Outcomes for...
Design Lab panel recap June 10–11, Adaptive Reimbursement was explored at the NEWDIGS LEAPS Design Lab by a panel representing a national provider system, commercial payers, a global biopharmaceutical...
View ArticleLEAPS Monthly Recap: June 2020
JUNE VIRTUAL DESIGN LAB RECAP Adaptive Reimbursement: Innovating for Patient Access & Better Outcomes for All Adaptive Reimbursement was explored at the NEWDIGS LEAPS Design Lab by a panel...
View ArticleFoCUS Monthly Recap: June 2020
WHITE PAPER Tracking the CAR-T revolution: Analysis of clinical trials of CAR-T and TCR therapies for the treatment of cancerWe look at all available FDA CAR-T/TCR clinical trials for the treatment of...
View ArticleNEWDIGS offers comment on CMS Proposed Rule supporting Value-Based Purchasing
On behalf of the NEWDIGS initiative / FoCUS Project, project team members submitted comments on the recent CMS Proposed Rule supporting Value-Based Purchasing (VBP) (CMS-2482-P). With active input...
View ArticleStakeholder collaboration, the gateway to patient-centered care
Dr Gigi Hirsch speaks in the Frances Hamburger Institute for Community Rheumatology (FHI) Inaugural Stakeholder Virtual Roundtable Webinar Summary courtesy of Frances Hamburger Institute for Community...
View ArticleFoCUS Monthly Recap: July 2020
RESEARCH BRIEF Pipeline analysis: 10x growth, but serious questions Updated projection of US durable cell and gene therapies product-indication approvals based on December 2019 development pipeline....
View ArticleLEAPS Monthly Recap: July 2020
Stakeholder collaboration, the gateway to patient-centered care Dr Gigi Hirsch speaks in the Frances Hamburger Institute for Community Rheumatology (FHI) Inaugural Stakeholder Virtual Roundtable...
View ArticleFoCUS Monthly Recap: December 2021
COMING SOON Paying for Cures Toolkit update in early ’22 After the holiday FoCUS will release a major update to the toolkit, including updates to the Pipeline and Individual Indication worksheets and...
View ArticleLEAPS Monthly Recap: January 2022
RECENT PUBLICATION LEAPS research in Precision Reimbursement published in Clinical Pharmacology & Therapeutics The article, “Precision Reimbursement for Precision Medicine: Using Real-World...
View ArticleFoCUS Monthly Recap: January 2022
JUST RELEASED Paying for Cures Toolkit updated with new pipeline modeling and financing strategies Today FoCUS released an updated and expanded version of its Paying for Cures Toolkit, which is...
View ArticleLEAPS leadership news: Kay Larholt retires, Fotios Kokkotos joins
In February 2022, Kay Larholt retired from her role as Director of Research for NEWDIGS, to stay on as a Senior Advisor. Fotios Kokkotos joined as NEWDIGS’ Director of Data Science. In this Fireside...
View ArticleLEAPS Monthly Recap: February 2022
WE’RE GROWING NEWDIGS searching for new director, program manager We’re searching for Director and Program manager talent—join our interdisciplinary think-and-do tank designing solutions to make...
View ArticleFoCUS Monthly Recap: February 2022
JUST RELEASED Paying for Cures Toolkit updated with new pipeline modeling and financing strategies FoCUS released an updated and expanded version of its Paying for Cures Toolkit, which is designed to...
View ArticleClik here to view.
How can self-insured employers prepare for the portfolio impact of highcost...
Share the research Self-insured employers (SIEs) currently rely on traditional stop-loss insurance to protect against unexpected high-cost claims, including those for cell and gene therapies. Given...
View ArticleLEAPS Monthly Recap: April 2022
NEW MEMBER NEWDIGS welcomes Takeda Pharmaceuticals as a new collaborator in the LEAPS Project Takeda Pharmaceutical, a global biopharmaceutical company committed to bringing Better Health and a...
View ArticleFoCUS Monthly Recap: April 2022
RESEARCH BRIEF How can self-insured employers prepare for the portfolio impact of high-cost gene therapies coming to market? Self-insured employers currently rely on traditional stop-loss insurance...
View ArticleNEWDIGS welcomes Takeda Pharmaceuticals as a new collaborator in the LEAPS...
Takeda Pharmaceutical, a global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide, has joined the Massachusetts Institute of Technology Center for...
View Article
